natgillin/translations-raw huggingface dataset:
wherein R1, A and m are as defined above, with a compound represented by formula (III): wherein R2, R3, n and q are as defined above and Z is a chlorine atom, OH or C1-4 alkoxy, or 
(ED HR P20160095 T1 pri čemu R', R? i n su kako je gore definirano, a Z je atom klora, -OH ili C,4 alkoksi ili (2) reakcije spoja predstavljenog formulom (IV): uk
Figures 1 through 9 are longitudinal views of various embodiments of the invention; 
(redni brojevi) su uzdužni presjeci raznih realizacija izuma,
creating a dosage form suitable for administration to the mammal from the pharmaceutical composition; and 
(b) izrada oblika za doziranje iz farmaceutskog pripravka koji je pogodan za primjenu kod sisavaca i
The cell according to claim 7, wherein the humanized antibody specific for the protofibrillar form of the A-B peptide comprises a heavy chain variable region comprising a sequence having at least 95% identity with SEQ ID NO: 6, and comprising a light chain variable region comprising a sequence having at least 99% identity with SEQ ID NO: 8. 
sadrži lagani lanac kojeg kodira sekvenca koja ima barem 80% identičnosti s jednom od nukleotidnih sekvenci SEQ ID NO: 3 i SEQ ID NO: 21 i/ili lagani lanac koji ima barem 80% identičnosti s jednom od polipeptidnih sekvenci SEQ ID NO: 4 i SEQ ID NO: 22.
A method according to claim 9, characterized by the sludge being heated with superheated steam having a temperature of 300 to 400 °C. 
Metoda u skladu s patentnim zahtjevom 9, karakterizirana zagrijavanjem mulja superzagrijanom parom temperature od 300 do 400°C.
Fig. 6 shows cross-section A of fig. 2, comprising the scope 2, the needle 3 and the tubular member 4. 
Prikazan je drugi prolaz za vođenje 11. Slika 6 prikazuje poprečni presjek A iz slike 2 koji sadržava endoskop 2, iglu 3 i cijevni element 4.
The thus-titrated solution was stood at a temperature of 30 to 37°C for 4 hours to 1 day and then centrifuged, and The thus-precipitated collagen was resuspended to a concentration of 1 to 30 mg/mL in weakly acidic solvent or PBS, and stored at 4°C. 
HR P20131129 TI odležavanja tako titrirane otopine kod temperature od 30 do 37""C tijekom 4 sata do 1 dana, te potom centrifugiranja; te resuspendiranja tako istaloženog kolagena na koncentraciju od 1 do 30 mg/ mL u slabo kiselom otapalu ili PBS, te potom pohranjivanja na 4*C.
A compound according to claim 46, wherein J is dimensioned to provide a macrocycle of 14 or 15 ring atoms. 
Spoj u skladu sa zahtjevom 46, naznačen time, da J je dimenzioniran tako da daje makrocikl sa 14 do 15 atoma prstena.
The tablet according to claim 2, comprising about 800 mg of aspirin, about 1600 mg of alkaline substances, and about 480 mg of ascorbic acid. 
Tableta prema zahtjevu 2, naznačena time da sadrži oko 800 mg aspirina, oko 1600 mg alkalnih tvari, te oko 480 mg askorbinske kiseline.
The compound or salt of claim 1 of the formula wherein R is hydrogen or methyl. 
Spoj ili sol u skladu s patentnim zahtjevom 1 formule [image], naznačen time što je R vodik ili metil.
reacting a compound of formula (11) wherein R1, R2 and R3 have the meanings defined in claim 1 or a mixed anhydride thereof, with the amine NHR4R5 wherein R4 and R5 have the meaning defined in formula (1) under the standard condition for preparing amides from a carboxylic acid or a mixed anhydride thereof and an amine. 
HN R, o (11) gdje Ry, R2 i Ra znače kao što je definirano u patentnom zahtjevu 1, ili njegovog miješanog anhidrida, s aminom NHR+Rs, gdje Ru i Rs znače kao što je definirano za formulu (1), u standardnim uvjetima dobivanja amida iz karboksilne kiseline ili njenog miješanog anhidrida i amina.
In some embodiments, R5 is selected from the group consisting of H, —C(═O)N(R9)2 and —CN. 
Spoj prema zahtjevu 6, naznačen time da R? je odabran iz skupine koja sadrži H, -C(=0)N(R*),, te -CN.
A combination comprising a therapeutically effective amount of a compound of formula (I) or (Ia) in free or salt form and, where possible, in pharmaceutically acceptable acid addition salt form and a second drug substance, said second drug substance being, e.g., for use in any of the particular indications set forth hereinabove. 
(4) kombinaciju koja obuhvaća terapeutski učinkovitu količinu spoja formule (1) ili (Ia) u slobodnom obliku ili u obliku soli 1, gdje je to moguće, u obliku farmaceutski prihvatljive kiselnske adicijske soli 1 druge ljekovite tvari, pri čemu spomenuta druga ljekovita tvar može biti, npr. za upotrebu kod bilo koje od gore navedenih posebnih indikacija.
In yet another embodiment of the dosage form, the total amount of non-polar impurities is less than 0.3 wt% relative to the amount of rasagiline. In yet another embodiment of the dosage form, the amount of N-(2-chloroallyl)-1(R)-aminoindan in the dosage form is less than 20 ppm relative to the amount of rasagiline. 
Oblik doziranja prema bilo kojem od patentnih zahtjeva 1-7, naznačen time, da je ukupna količina nepolarnih onečišćenja manja od 0,3 tež.% u odnosu na količinu rasagilina, ili kod čega je u obliku doziranja količina od N-(2- kloroalil)-1(R)-aminoindana manja od 20 ppm, prvenstveno manja od 4 ppm u odnosu na količinu rasagilina.
the length of L3 is at least twice the length of L1;and the linkers provide sufficient mobility for pairing of VL1 and VH1, and for pairing of VL2 and VH2, and wherein the polypeptides of formula I and the polypeptides of formula II form a cross-over light chain-heavy chain pair. 
L; je duljine 1 do $ ostataka amino kiseline; i L, je duljine 1 do 3 ostataka amino kiseline; i pri čemu polipeptidi s formulom I i polipeptidi s formulom II tvore prijelazni par laki lanac-teški lanac.
Buffer is oxygenated with 95% 02/5% CO2 for 10 min at 37° C. and pH is adjusted 7.4. The incubation is started by adding tissue to a final assay volume of 0.2 mL. After 15 min incubation with radioligand at 37° C., samples are filtered directly on Unifilter GF/C glass fiber filters (soaked for 1 hour in 0.1% polyethylenimine) under vacuum and immediately washed with 3×0.2 mL assay buffer. 
Pufer je oksigeniran s 95% 0;/5% CO, tijekom 10 min na 37C 1 pH je podešen na 7,4. inkubacija je započeta dodavanjem tkiva do konačne pokusne količine od 0,2 mL Nakon 16 min inkubacije s radioligandom na 37?C uzorci su filtrirani izravno kroz Unifilter GE/C filtere od staklene vune (namakane 1 sat u 0,1% polietileniminu) u vakuumu i odmah isprani s 3x0,2 ml pokusnog pufera.
The conjugate or composition for use as described in claim 15, wherein said cancer is multiple drug resistant. 
Konjugat ili pripravak za uporabu kako je opisano u zahtjevu 15, naznačen time da je navedeni karcinom višestruko rezistentan na lijekove.
xxiii) said in vitro -synthesized RNA contains one or more modified ribonucleosides, selected from the group consisting of pseudouridine, 1-methylpseudouridine, 5-methyluridine, 2'-O-methyluridine, 2-thiouridine, and 5-methylcytidine in place of at least a portion of the corresponding unmodified canonical ribonucleoside; and/or 
Obrađeni sastav ribonukleinske kiseline u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što navedeni sastav ribonukleinske kiseline ili ssRNA ili mRNA kodira najmanje jedan protein odabran iz skupine koja se sastoji od:
The CB2 receptor is also expressed on other immune system cells, such as lymphoid cells (S. Galiegue, et al., Eur J Biochem, 232, 54-61 (1995)). 
CB-2 receptori također se intezivno ekspresiraju u drugim stanicama imunološkog sustava, kao što su limfne stanice (S. Galiegue, et. al., Eur J Biochem, 232, 54-61 (1995)).
BAC as an anti-microbial preservative, the concentration of BAC in the composition being greater than 0.00001 w/v% but less than 0.0035 w/v%; and water. A composition as in claim 1 wherein the composition satisfies Ph. 
BAC kao antimikrobni konzervans, te je koncentracija BAC u pripravku veća od 0,00001 m/v% ali manja od 0,0035 m/v%; i vodu, pri čemu je terapeutsko sredstvo suspendirano u otopini, i pri čemu se osmolalnost suspenzije nalazi u rasponu od 240 do 360 mOsm.
W is L-Y-glutamyl; X is cyclopentyl, cyclohexyl, furyl, thienyl, or pyridinyl, or optionally substituted phenyl; especially cyclohexyl or 3-thienyl, or phenyl optionally substituted with fluoro, chloro, cyano, methyl, hydroxy, or methoxy, especially where the phenyl is unsubstituted or has 1 substituent in the 4-position; such as phenyl, 4-chlorophenyl, and 4-hydroxyphenyl; 
Y je po izboru supstituirani Cs.g cikloalkil, po izboru supstituirani C5.g cikloheteroalkil, po izboru supstituirani fenil ili po izboru supstituirani Csg heteroaril; posebno Y je ciklopentil, cikloheksil, tienil, furil, piridinil ili po izboru supstituirani fenil; prikladnije cikloheksil ili još prikladnije fenil, po izboru supstituiran sa 1 ili 2 floro, kloro, metil, hidroksi, metoksi ili triflorometil skupine; kao kad je fenil nesupstituiran, ili je supstituiran i jedan od supstituenata je u 4-poziciji, posebno kad je ondje samo jedan supstituent;
An antibody directed against an extracellular part of Sortilin and capable of inhibiting binding of a pro-neurotrophin to a binding site of a Sortilin receptor, wherein the antibody binds to the binding motif for pro-neurotrophin according to SEQ ID NO: 25, 26, 27 or 28 or a fragment thereof. 
Antitijelo usmjereno protiv vanćelijskog dijela sortilina i sposobno inhibirati vezanje proneurotrofina na mjesto vezivanja na receptor sortilina, gdje je antitijelo usmjereno protiv sekvence koja se sastoji od RGGRIFRSSDFAKNF za uporabu u liječenju ljudskih neurodegenerativnih poremećaja.
The video decoding apparatus of claim 1, wherein the decoder is configured for storing a context variable of the current maximum coding unit finally decoded in the first slice segment if the second information indicates that the current maximum coding unit is at the end of the first slice segment. The video decoding apparatus of claim 1, wherein the decoder is further configured for determining whether a dependent slice segment of the picture can be included or not based on the first information obtained from a picture parameter set of the bitstream, determining whether the current maximum coding unit is a final maximum coding unit or not based on the second information obtained from data of the current maximum coding unit among data of each of slice segments of the bitstream, and obtaining a bin string from the data of the current maximum coding unit. 
pri čemu je jedinica za entropijsko dekodiranje nadalje konfigurirana za određivanje položaja ulaznih točaka na temelju pomaka koji je 1 veći od broja naznačenog četvrtom informacijom dobivenom iz toka bitova; pri čemu je jedinica za entropijsko dekodiranje nadalje konfigurirana za dekodiranje drugog segmenta odsječka koji je smješten poslije prvog segmenta odsječka u redoslijedu dekodiranja u trenutnoj slici pomoću pohranjenih varijabli konteksta i ulaznih točaka, pri čemu drugi segment odsječka je ovisan segment odsječka, i pri čemu se broj i položaji ulaznih točaka određuju ako se sinkronizacija može provesti za varijable konteksta u trenutnoj slici.
A method of generating an immune response in a subject comprising administering the composition of any one of claims 1, 2 or 3 to the subject. 
Smjesa iz bilo kojeg od patentnih zahtjeva 1-7, naznačena time, što se koristi za generiranje imunološkog odgovora kod subjekta.
The patient is one who has exhibited abnormal biomarkers of liver function after pirfenidone administration as is described above with respect to the invention for administering pirfenidone to a patient for treating idiopathic pulmonary fibrosis or a patient who would benefit from pirfenidone administration. In particular, the disclosure includes the use of pirfenidone in the manufacture of a medicament for treating a patient with idiopathic pulmonary fibrosis, said patient having exhibited a Grade 2 abnormality in one or more biomarkers of liver function after pirfenidone administration, wherein said patient is administered pirfenidone at doses of 2400 mg/day or 2403 mg/day. 
Upotreba pirfenidona u proizvodnji lijeka za liječenje pacijenta s idiopatskom pulmonarnom fibrozom (IPF), pri čemu pacijent ima razinu 2 abnormalnosti u jednom ili više biomarkera funkcije jetre poslije davanja pirfenidona, i ima abnormalnu razinu alanin transaminaze (ALT) i/ili aspartat transaminaze (AST) koji je više od 2.5- do 5- puta povećana u usporedbi s gornjom granicom normalnih vrijednosti, poslije davanja pirfenidona, gdje (a) spomenutom pacijentu je davan pirfenidon u dozama od bar 1600 mg/dnevno ili 1602 mg/dnevno.
System according to claim 8 or 9, wherein the pipeline (P) comprises a plurality of steams traps (S) for collecting the liquid water that may condense inside the pipeline, each steam trap being formed as a water column seal. 
Sustav sukladno zahtjevu 2, pri čemu cjevovod (P) sadrži više komora (S) za prikupljanje tekuće vode koja bi kondenzirala unutar cjevovoda, svaka komora formirana je kao vodena brtva.
Bishydrazide 1-1 from Step A (43.2 g, 0.21 mol) in ACN (82 mL) was cooled to 5 °C. Phosphorus oxychloride (32.2 g, 0.21 mol) was added, maintaining the temperature below 10 °C. The mixture was heated to 80 °C and aged at this temperature for 24 h until HPLC showed less than 2 area% of 1-1 . 
Bis hidrazid 1-1 iz Koraka A (43.2 g, 0.21 mol) u ACN-u (82 mL) je ohlađen na 5%C. Fosforni oksiklorid (32.2 g, 0.21 mol) je dodan, održavajući temperaturu ispod 10%C, Smjesa je zagrijana na 80%C i ostavljena na ovoj temperaturi 24 h, dok HPLC nije pokazao manje od 2 površinska% od I-I.
The antibody of claim 15, wherein the heavy chain is connected to a light chain by a flexible linker to form a single-chain antibody. 
Antitijelo ili antigen vezujući fragment istog prema jednom od zahtjeva 1-10, naznačen time da su teški lanac 1 laki lanac povezani fleksibilnom poveznicom, čime nastaje antitijelo s jednim lancem.
In view of the above, the present invention also provides a method of controlling the volumetric shrinkage of a composite material upon curing, comprising the step of: 
S gornjeg aspekta, ovaj izum također prikazuje metodu kontroliranja volumetrijskog skupljanja kompozitnog materijala nakon očvršćivanja, a sastoji se od sljedećih koraka:
The arrangement according to claim 1, wherein the at least one hydrofoil has different profile thicknesses and/or profile lengths, viewed in the longitudinal direction thereof, wherein in particular the region of the at least one hydrofoil facing the shaft bracket has a larger profile thickness than the remainder of the at least one hydrofoil, and/or wherein in particular the profile of the at least one hydrofoil tapers from its end facing the shaft bracket to its end facing away from the shaft bracket with reference to its profile thickness and/or its profile length. 
Sustav u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što najmanje jedno hidrokrilo kada se gleda u svom uzdužnom smjeru ima različite debljine profila i/ili duljine profila, gdje osobito područje najmanje jednog hidrokrila okrenuto prema konzoli osovine (10) ima veću debljinu profila nego ostatak najmanje jednog hidrokrila, 1/ili gdje se osobito profil najmanje jednog hidrokrila suzuje od njegovog kraja okrenutog prema konzoli osovine (10) prema svom kraju okrenutom od konzole osovine (10) u odnosu na debljinu njegovog profila i/ili duljinu njegovog profila.
m is selected from the group consisting of 0, 1, 2, 3, 4 and 5; 
m je izabran iz grupe koju čine 0, 1, 2, 3, 4 i 5;
The method of any of items 32 to 45, further comprising the step of reacting 2-amino-6-nitrobenzoic acid with an activated acetic acid in a solvent to form 2-methyl-5-nitro-4 H -benzo[d][1,3]oxazin-4-one before reacting 2-methyl-5-nitro-4 H- benzo [d][1,3]oxazin-4-one with 3-aminopiperidine-2,6-dione or a salt thereof. The method of item 46, wherein the activated acetic acid is acetyl chloride. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 11 do 13, naznačen time što dodatno uključuje korak reakcije 2-amino-6-nitrobenzojeve kiseline s aktiviranom octenom kiselinom u otapalu kako bi se dobilo 2-metil-5-nitro- 4H-benzol[d][1,3]oksazin-4-on, prije reakcije 2-metil-5-nitro-4H-benzol[d][1,3]oksazin-4-ona s 3-aminopiperidin2,6-dionom, ili njegovom solju; po mogućnosti gdje je aktivirana octena kiselina acetil-klorid ili acetanhidrid.
In other embodiments, the fraction is at least any one of these values. 
Postupak prema zahtjevu 13, naznačen time, da frakcija predstavlja najmanje 0,5% humanog genoma.
is a hydrogen atom or C1-6 alkyl which may be substituted with a hydroxy; 
R, jest atom vodika ili Ci.4 alkil koji može biti supstituiran sa hidroksijem;
The quality and quantity of the coating substance are to be determined on the basis of the dissolution profile, that is the desired dependence of the release on time. 
Kakvoća i kvaliteta tvari za prevlaku mogu se odrediti temeljem profila topljivosti, dakle vremenskom funkcijom otpuštanja o vremenu.
The composition for the use of any one of claims 1 to 3, wherein a first dose of the composition is to be administered for a first period of time and consecutively a second dose of the composition is to be administered for a second period of time, wherein the second dose exceeds the first dose. 
Pripravak namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se prvu dozu pripravka primjenjuje tijekom prvog vremenskog perioda, nakon toga se drugu dozu pripravka primjenjuje tijekom drugog vremenskog perioda, gdje je druga doza veća od prve doze.
reacting a compound of formula VIII 
(v) reakciju spoja formule VIII
An electrically heated smoking system according to any of claims 1 to 7, wherein the electrically insulating substrate is tubular and the one or more electrically conductive tracks are on the inside of the tubular electrically insulating substrate. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time što se nanošenje navedene bezvodne tekućine na bazi silana provodi raspršivanjem navedene bezvodne tekućine na bazi silana na profiliranu površinu.
A vector comprising the nucleotide sequence set forth in SEQ ID NO: 19. 
Vektor sadržeći nukleotidnu sekvencu utvrđenu u SEQ ID NO: 19.
Tribulus terrestris, with a 40% saponin content, 
- Tribulus terrestris sa udjelom saponina od 40%,
A pyrazole compound represented by the formula (I) or its salt: wherein 
"Spoj pirazola predstavljenog formulom (I) ili njegova sol: naznačen time, da
The crystalline monohydrochloride salt is not described. 
Nije opisana monohidrokloridna sol.
A solid preparation comprising tofogliflozin as an active ingredient, lactose hydrate, crystalline cellulose, croscarmellose sodium, and hydrogenated oil and/or magnesium stearate. The solid preparation of [27] having a dosage form selected from a tablet, a capsule, or a granule. 
Farmaceutski pripravak naznačen time što je tableta proizvedena postupkom prema bilo kojem od zahtjeva 1 do Farmaceutski pripravak prema zahtjevu 14, naznačen time što o aktivni sastojak sadrži tofogliflozin, laktoza hidrat, kristalnu celulozu, natrijevu kroskarmelozu, te hidrogenirano ulje i/ili magnezijev stearat.
Use of a 9- cis- retinal derivative having a structure represented by Formula I wherein A is CH2OR and R forms a retinyl ester, in the preparation of a medicament for use in the treatment of an endogenous 11- cis -retinal deficiency in a human subject. 
Upotreba derivata 9-cis-retinala čija je struktura predstavljena Formulom I, HR P20140116 TI (D pri čemu A predstavlja CH2OR, a R tvori Tetinil ester, naznačena time, da je to upotreba za pripravu lijeka za liječenje endogene deficijencije 11-cis- retinala kod ljudskog subjekta.
See, for example, U.S. Pat. 
Vidi, na primjer, Hille et al., U.S. Pat.
a CDRH1 sequence that corresponds to amino acid residues 31 to 35 (DYYMY) of SEQ ID NO: 31, wherein one of these amino acid residues is optionally a different amino acid residue; 
(i) CDRHI sekvencu koja odgovara aminokiselinskim ostacima 31 do 35 (DYYMY) iz SEK ID BR: 31, gdje jedan od ovih aminokiselinskih ostataka je po izboru različit aminokiselinski ostatak;
The subject invention also provides a process for validating a batch of N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or a salt thereof for distribution. The subject invention also provides a process for preparing a pharmaceutical product comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-l-methyl-2-oxoquinoline-3-carboxamide or a salt thereof and a pharmaceutically acceptable carrier, wherein the pharmaceutical product has not more than a total of 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of the oxidation decomposition products 2-Chloro-6-(1-ethyl- N -methyl-2-oxoindoline-3-carboxamido) benzoic acid, 1 H,3 H -spiro[5-chloro-1-methylquinoline-2,4-dione-3,3'-[1]ethylindolin-[2]-one], and 5-Chloro- N -ethyl-3-hydroxy-1-methyl-2,4-dioxo- N -phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide. 
HR P20140138 T1 PATENTNI ZAHTJEVI Postupak za validaciju šarže farmaceutskog produkta koji sadrži spoj N-etil-N-fenil-1,2-dihidro-4-hidroksi-5-kloro-1-metil-2-oksokinolin-3-karboksamid ili njegovu sol, te farmaceutski prihvatljiv nosilac za distribuciju, naznačen time, da obuhvaća: a) podvrgavanje uzorka šarže ispitivanju stabilnosti; b) određivanje ukupne količine produkta oksidacijskog raspadanja u uzorku šarže nakon ispitivanja stabilnosti: i c) validaciju šarže za distribuciju, samo ako uzorak šarže nakon ispitivanja stabilnosti ne sadrži više od ukupno 0,5 1te2.% produkata oksidacijskog raspadanja N-etil-N-fenil-1,2-dihidro-4-hidroksi-5-kloro-1-metil-2-oksokinolin-3-karboksamida, u odnosu na N-etil-N-fenil-1,2-dihidro-4-hidroksi-5-kloro-1-metil-2-oksokinolin-3-karboksamid.
a hollow piercer adapted for piercing the piercable closure; a closable dispensing tube connected to the hollow piercer; where the base unit and the neck part are provided at a lower end of the container, and where said housing of the base unit has an outer wall extending axially beyond said neck part in a downwards direction substantially in extension of the wall of the collapsible container, and where said base part has a surface adapted for supporting said outer wall extension. 
cijev za točenje koju se može zatvoriti i koja je spojena sa šupljim bušilom; pri čemu su osnovna jedinica i vratni dio predviđeni na donjem kraju spremnika, i gdje spomenuto kućište osnovne jedinice ima vanjsku stijenku koja se proteže aksijalno iza spomenutog vratnog dijela u smjeru prema dolje uglavnom u produžetku stijenke sklopivog spremnika, i gdje spomenuti osnovni dio ima površinu prilagođenu tako da ona podupire spomenuti produžetak vanjske stijenke.
A process as in any one of claims 1 and 2 wherein the (C1-C5)alkyl methanesulfonate(s) is(are) selected from methyl methanesulfonate, ethyl methanesulfonate and isopropyl methanesulfonate. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 i 2, naznačen time što se jedan ili više (C1-C5) alkil-metansulfonata bira između metil-metansulfonata, etil-metansulfonata i izopropil-metansulfonata.
The Wave-generating apparatus (1), according to claim 4, wherein the profile (5) is inflatable. 
Uređaj za generiranje valova (1), sukladno zahtjevu 4, pri čemu je profil (5) moguće napuhati.
The expression “pharmaceutically acceptable salt, solvate or prodrug thereof” describes any pharmaceutically acceptable salt, ester, solvate or any other compound that, administered to a patient (directly or indirectly) r provides a compound described herein. 
Izraz "farmaceutski prihvatljiva sol, ili njezin solvat" znači bilo koju farmaceutski prihvatljivu sol, ester, solvat ili bilo koji drugi spoj koji dat pacijentu (izravno ili posredno) daje ovdje opisan spoj.
Especially in the field of coffee machines, machines have been widely developed in which an initially hermetically sealed capsule containing beverage ingredients is inserted (while still being sealed) in an opened extraction module. 
Naročito u području strojeva za kavu, bili su jako razvijeni strojevi kod kojih se u početku hermetički zatvorena čahura koja sadržava sastojke za napitak umetne (dok je još uvijek hermetički zatvorena) u otvoreni ekstrakcijski modul.